← FDA DRUG APPROVALS

FDA ANDA · ANDA202741

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

Sponsor: XIROMED

APPLICATION
ANDA202741
TYPE
ANDA
ORIGINAL APPROVAL
2015-02-20
LATEST ACTION
2024-01-05
ROUTE
ORAL-28
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOLPrescription
ETHINYL ESTRADIOL 0.03MG, NORETHINDRONE ACETATE 1.5MG · TABLET · ORAL-28

Approval history

2024-01-05Labeling · Supplement 8 · standardAP
2024-01-05Labeling · Supplement 6 · standardAP
2018-11-08Labeling · Supplement 2 · standardAP
2018-11-08Labeling · Supplement 3 · standardAP
2015-02-20UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →